Latest open letter sent to the Company. There needs to be...

Latest open letter sent to the Company. There needs to be greater pressure placed on the Company by shareholders.

OpenLetter to the Board and Management of Chimeric Therapeutics (ASX:CHM)

To WhomIt May Concern,

As a concerned shareholder, I am once again writingto express deep disappointment in the ongoing failure to meet and communicatekey milestones. Investors have been patient and supportive, yet the lack oftimely updates, the misuse of vague timelines, and failure to follow through onpublic commitments is eroding trust and damaging the Company’s credibility.

At the recent NWR Communications HealthcareConference (March 2025), the CEO made several forward-looking statements whichremain unfulfilled and unaddressed:

1. CHM CDH-17 – Fourth site “going through site initiation” and to be announced “shortly.”
2. Patient Five – To be dosed “shortly.”
3. Patient Two Day 90 Results – “Soon.”
4. Patient Two bloods – “As soon as I have them, I’ll announce them.”
5. CORE-NK Frontline Trial – “Hopefully we’ll have some results for that soon.”
6. Case Western Patients – Updates on further three patients to be shared “as soon as I have it.”
7. CHM CDH-17 in Australia – Stated aim to bring this to Australia in H2 2025, despite stating at the RIU Conference in August 2024 that it would be “within six months.”

How many of these seven key milestones have beenannounced? None.
How many have been hit? We do not know, because there has been no disclosure.

Compounding this is a statement made by the CEO inFebruary 2025 during an interview with Kalkine Media:

“There will be ongoing updates about our reallyexciting frontline AML trial (CORE-NK) coming out shortly. But because we’re ina partnership with MD Anderson on that one, we’ll probably save the data andtake it to ASH at the end of the year.”

Let’s be clear — it has now been over 14 monthssince the first patient was dosed, and not one data point has been announced.This is not acceptable and, in my opinion, is in breach of ASX Listing Rule 3.1and Section 674 of the Corporations Act 2001, which mandate continuousdisclosure of price-sensitive information.

If that were not concerning enough, the Company hasnow turned to shareholders “cap in hand” for a capital raise — after reportedlyfailing to secure institutional support through brokers. The raise has now beenextended, indicating investor hesitation. In my view, the failure to raise therequired capital reflects a reputation issue rooted in the lack of transparencyand consistent under delivery on public commitments.

The Company’s unwillingness to address these issuesonly adds to investor frustration. After sending a private, constructivemessage to the CEO offering solutions to improve corporate governance, rebuildtrust, and get the Company back on track — I was blocked. That action speaksvolumes.